Terms ending in 2030
Every in-force patent on AbbVie Inc.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,546,410 | Heteroaryl-Fused Macrocyclic Pyrimidine Derivatives In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US D746,871 | Interface Portion of a Pump In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 9,394,363 | Antibodies to Receptor of Advanced Glycation End Products (RAGE) and Uses Thereof In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 9,035,027 | Dual Variable Domain Immunoglobulins and Uses Thereof In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,420,081 | Antibody Formulations and Methods of Making Same In force · High confidence | AbbVie Biotechnology Ltd. | In force | High confidence | |
| US 8,404,719 | Substituted Piperidinylcarbonylbenzenesulfonamides as Calcium Channel Blockers In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,093,396 | Benzthiazole Inhibitors of Poly(ADP-RIBOSE)polymerase In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,603,477 | Use of ANTI-CS1 Antibodies for Treatment of Rare Lymphomas In force · High confidence | Abbott Biotherapeutics Corp. | In force | High confidence | |
| US 9,353,091 | Antiviral Compounds and Uses Thereof In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 9,637,478 | Antiviral Compounds and Uses Thereof In force · High confidence | AbbVie Inc. | In force | High confidence | |
| 48 more term ends in 2030 · Pro | |||||
10 of 58 patents shown. Soonest term end first, then patent number.
Pro members see all 58.
57 of these are in force and held by AbbVie Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.